pubrio
WuXi Biologics

WuXi Biologics

China · Pharmaceuticals

Pharmaceuticals

Biotechnology

Healthcare

Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

Company Insights
Company Overview

2010

Founded

Pharmaceuticals

Industry

China

Location

2,061,965

Ranking

2,900 employees

Size

Similar Companies
Similiar Companies

Get full access to view complete information

Frequently Asked Questions Regarding WuXi Biologics

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

Talk to Our Team
Start Journey Image
pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​

Call Center

85259256922

Our Location

15th Floor ADGM Square, UAE

Social Network

© Pubrio 2026